Simplex Trading
TRVI icon

Simplex Trading’s Trevi Therapeutics TRVI Stock Holding History

Simplex Trading’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$934K Buy
50,100
+31,700
+172% +$461K ﹤0.01% 2864
2026
Q1 		$220K Buy
18,400
+17,700
+2,529% +$198K ﹤0.01% 4200
2025
Q4 		$8.76K Sell
700
-105,000
-99% -$1.21M ﹤0.01% 7069
2025
Q3 		$967K Sell
105,700
-34,900
-25% -$262K ﹤0.01% 3082
2025
Q2 		$769K Sell
140,600
-4,000
-3% -$24.9K ﹤0.01% 3059
2025
Q1 		$909K Buy
144,600
+143,900
+20,557% +$686K ﹤0.01% 2793
2024
Q4 		$2K Buy
+700
New +$2.24K ﹤0.01% 8092

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Simplex Trading's TRVI Position: Q2 2026 in Review

Simplex Trading increased its Trevi Therapeutics (TRVI) stake by 381% in Q2 2026, buying an estimated $1.12M and bringing the position to 97,557 shares worth $1.82M. The position accounts for ﹤0.01% of the portfolio, ranked #2145.

Simplex Trading first reported a position in TRVI in Q4 2022 and has held it in 8 quarters since. 219 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

  • Simplex Trading held 97,557 shares of Trevi Therapeutics worth $1.82M as of Q2 2026.
  • Simplex Trading bought 77,280 Trevi Therapeutics shares in Q2 2026, an estimated $1.12M.
  • Trevi Therapeutics made up ﹤0.01% of Simplex Trading's portfolio in Q2 2026, its #2145 holding.
  • Simplex Trading first reported a position in Trevi Therapeutics in Q4 2022 and has held it in 8 quarters since.
  • 219 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on Simplex Trading's 13F filing for Q2 2026, filed 12 Aug 2026.